Last reviewed · How we verify
NCT03410511: PGGICF
Propylene Glycol/Glycerol Intake and Cardiorespiratory Function
NA trial testing Nicotine free intake in Lung Injury in 30 participants. Completed in 30 June 2020.
30 June 2019
Quick facts
| Lead sponsor | Université Libre de Bruxelles |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 15 January 2018 |
| Primary completion | 30 June 2019 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Nicotine free intake
- Nicotine intake
- Cessation intake
Conditions studied
- Lung Injury — all drugs for Lung Injury →
Sponsor
Université Libre de Bruxelles — full company profile →
Who can join
Adults 18 to 60, male only, with Lung Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Propylene glycol/Glycerol intake is increasingly popular. The propylene glycol/glycerol intake effects on cardiorespiratory function are unknown.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Short halt in vaping modifies cardiorespiratory parameters and urine metabolome: a randomized trial.
Chaumont M, Tagliatti V, Channan EM, Colet JM, et al · · 2020 · cited 25× · PMID 31721596 · DOI 10.1152/ajplung.00268.2019
Verify or expand the search:
- PubMed search for NCT03410511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Injury
Currently open trials in the same condition.
- NCT06296173 — Open Lung Protective Extubation Following General Anesthesia · NA · recruiting
- NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting
- NCT05642832 — Feasibility of Reducing Respiratory Drive Using the Through-flow System · NA · recruiting
- NCT06203405 — The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Ra · NA · recruiting
- NCT06416709 — Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases · Phase 1, PHASE2 · recruiting
Other Université Libre de Bruxelles trials
Trials by the same sponsor.
- NCT07568405 — The Effect of Remifentanil on the Objectively Measured Pressure Pain Threshold · NA · enrolling by invitation
- NCT07513974 — Objective Measurement of the Mechanical Pain Threshold With an Algometer for Predicting Intraoperative Opioid Consumptio · NA · recruiting
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06959069 — Impact of Intermittent Fasting on Sleep and Quality of Life · NA · recruiting
- NCT06666101 — Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03410511 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université Libre de Bruxelles
- Last refreshed: 3 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03410511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing